Myeloproliferative Neoplasms

Top Story

FDA grants orphan drug designation to SY-1425 for acute myeloid leukemia

August 21, 2017

The FDA granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia, according to the drug’s manufacturer.

SY-1425 (Syros Pharmaceuticals) is an oral, first-in-class selective retinoic acid receptor alpha agonist.

Fox Chase Cancer Center announces appointments

August 19, 2017
Fox Chase Cancer Center announced several appointments. lHayley E. Walker, MD, has joined the department of medicine as a hospitalist.

Ten important updates in hematologic malignancies

August 18, 2017
HemOnc Today presents 10 advances in the treatment of leukemia, lymphoma, myeloma and myeloproliferative neoplasms that may be relevant to your practice and help…
In the Journals Plus

Vorinostat may prevent graft-versus-host disease after unrelated donor bone marrow transplant

August 15, 2017
Vorinostat appeared safe and effective combined with standard graft-versus-host disease prophylaxis for patients undergoing matched unrelated donor hematopoietic stem…
More Headlines »

Polycythemia Vera: Aligning Real World Practices With Current Best Practices

This activity is supported by an independent educational grant from Incyte Corporation.

Ruben A. Mesa, MD, provides practical insights into treating polycythemia vera in this video series. In addition to…
More »

VIDEO: Effort to systematize approach to medicine has ‘taken on a life of its own’

January 20, 2016
More »
Resource Centers


Multiple Myeloma Patient Management: Embracing New Advancements, Overcoming New Challenges

Support for this activity has been provided through educational grants from Amgen; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

The multiple myeloma clinical landscape has evolved significantly, with not only 10 new drugs but also new staging…
More »